Share on StockTwits

Vitamin Shoppe (NYSE:VSI) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research note issued on Thursday. They currently have a $37.90 price objective on the stock. Zacks‘s price objective points to a potential downside of 4.92% from the stock’s previous close.

A number of other analysts have also recently weighed in on VSI. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Vitamin Shoppe in a research note on Wednesday, August 6th. They now have a $50.00 price target on the stock, down previously from $55.00. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Vitamin Shoppe in a research note on Wednesday, August 6th. They now have a $49.00 price target on the stock, down previously from $54.00. Finally, analysts at Longbow Research reiterated a “buy” rating on shares of Vitamin Shoppe in a research note on Wednesday, August 6th. They now have a $55.00 price target on the stock, down previously from $59.00. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $49.32.

Vitamin Shoppe (NYSE:VSI) traded up 0.08% on Thursday, hitting $39.89. 448,451 shares of the company’s stock traded hands. Vitamin Shoppe has a 1-year low of $36.90 and a 1-year high of $55.20. The stock has a 50-day moving average of $40.97 and a 200-day moving average of $43.86. The company has a market cap of $1.217 billion and a price-to-earnings ratio of 18.78.

Vitamin Shoppe (NYSE:VSI) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.62 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.63 by $0.01. The company had revenue of $306.20 million for the quarter, compared to the consensus estimate of $306.09 million. During the same quarter in the prior year, the company posted $0.60 earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Analysts expect that Vitamin Shoppe will post $2.27 EPS for the current fiscal year.

Vitamin Shoppe, Inc is a specialty retailer and direct marketer of vitamins, minerals, herbs, specialty supplements, sports nutrition and other health and wellness products.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.